CM512
Phase 2Biologic
CM512 is one of 134 biologic programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 2.
6
Indications
8
Total Trials
7
Active Trials
133
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
Xolair
RochePreclinical
CM512
KKeymed Biosciences Co.Ltd
Phase 2
Aciphex
Akero TherapeuticsPreclinical
Atrovent
Boehringer IngelheimPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Paracetamol
GSKPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Ozone
TTanta University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis3 trials
Chronic Rhinosinusitis1 trial
Chronic Spontaneous Urticaria1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CM512. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- KKeymed Biosciences Co.Ltd